Wednesday, August 24, 2016

Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3

Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3

Alvin Kung, Ying-Chu Chen, Marianne Schimpl, Feng Ni, Jianfa Zhu, Maurice Turner, Henrik Molina, Ross Overman, and Chao Zhang

Department of Chemistry and Loker Hydrocarbon Research Institute, and Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, United States
Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Building 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, United Kingdom
Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
Proteomic Resource Center, The Rockefeller University, New York, New York 10065, United States
J. Am. Chem. Soc., 2016, 138 (33), pp 10554–10560
DOI: 10.1021/jacs.6b05483
*zhang.chao@usc.edu

Oncogenic KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition

Minh V. Huynh, Derek Parsonage, Tom E. Forshaw, Venkat R. Chirasani, G. Aaron Hobbs, Hanzhi Wu, Jingyun Lee, Cristina M. Furdui, Leslie B. P...